Interest in medical therapy for celiac disease

Tennyson, Christina A.; Simpson, Suzanne; Lebwohl, Benjamin; Lewis, Suzanne K.; Green, Peter H.

doi:10.1177/1756283x13492580

Cited by 36 publications

(30 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Stevens & Rashid (5) Canada Cereal-based General grocery stores On average, gluten-free products were 242% more expensive than regular products 3 Singh & Whelan (6) UK Cereal-based Noncereal-based…”

Section: Discussionmentioning

confidence: 99%

The economic burden of gluten‐free products and gluten‐free diet: a cost estimation analysis in Greece

Panagiotou

Kontogianni

2017

J Human Nutrition Diet

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

The economic burden of gluten‐free products and gluten‐free diet: a cost estimation analysis in Greece

Panagiotou

Kontogianni

2017

J Human Nutrition Diet

View full text Add to dashboard Cite

show abstract

“…Patients both in the United States [2] and England [3] have indicated that they are dissatisfied with the gluten-free diet and would like the availability of additional therapies. A glutenase preparation (latiglutenase) was tested in a large trial that failed to fulfil the primary endpoint of mucosal healing.…”

Section: Discussionmentioning

confidence: 99%

“…In genetically susceptible individuals, intestinal inflammation is triggered by the ingestion of gluten derived from cereals such as wheat, rye, or barley, leading to crypt hyperplasia and villous atrophy. Although patients want additional therapies [2,3], the only treatment currently available consists of a gluten-free diet (GFD).…”

Section: Introductionmentioning

confidence: 99%

Latiglutenase Improves Symptoms in Seropositive Celiac Disease Patients While on a Gluten-Free Diet

et al. 2017

Self Cite

View full text Add to dashboard Cite

Background and Aims Celiac disease (CD) is a widespread condition triggered by dietary gluten and treated with a lifelong gluten-free diet (GFD); however, inadvertent exposure to gluten can result in episodic symptoms. A previous trial of latiglutenase (clinicaltrials.gov; NCT01917630), an orally administered mixture of two recombinant gluten-specific proteases, was undertaken in symptomatic subjects with persistent injury. The primary endpoint for histologic improvement was not met, presumably due to a trial effect. In this post hoc analysis we investigated the efficacy of latiglutenase for reducing symptoms in subgroups of the study participants based on their seropositivity. Methods The study involved symptomatic CD patients following a GFD for at least one year prior to randomization. Patients were treated for 12 weeks with latiglutenase or placebo. Of 398 completed patients 173 (43%) were seropositive at baseline. Symptoms were recorded daily and weekly symptom scores were compiled. P-values were calculated by analysis of covariance (ANCOVA). Results A statistically significant, dose-dependent reduction was detected in the severity and frequency of symptoms in seropositive but not seronegative patients. The severity of abdominal pain and bloating was reduced by 58% and 44%, respectively, in the cohort receiving the highest latiglutenase dose (900 mg, n=14) relative to placebo (n=54). Symptom improvement increased from week 6 to week 12. There was also a trend toward greater symptom improvement with greater baseline symptom severity. Conclusions Seropositive CD patients show symptomatic improvement from latiglutenase taken with meals and would benefit from the availability of this treatment.

show abstract

“…Currently, the Celiac Dietary Assessment tool (CDAT) is the most widely used scoring system. The CDAT is a seven-item questionnaire that has been used and validated in six studies to date, involving 1855 patients (35,44,(46)(47)(48)(49) . The CDAT has yet to be compared to histology for adherence but was found to correlate highly with dietetic evaluations for assessing adherence (44) .…”

Section: Adherence Scoresmentioning

confidence: 99%

Long‐term care for patients with coeliac disease in the UK: a review of the literature and future directions

Kurien

Trott

Sanders

2016

J Human Nutrition Diet

View full text Add to dashboard Cite

Coeliac disease is a common digestive disorder that affects 1% of adults. It is characterised by mucosal damage of the small intestine caused by dietary gluten. The main treatment for coeliac disease is a lifelong gluten‐free diet, which can reduce morbidity and mortality and also improve quality of life. Despite the benefits, adhering to this diet is often challenging, with patients often struggling to sustain dietary restriction. Structured follow‐up for coeliac disease is recommended in international guidelines for improving adherence and for detecting complications;however, uncertainty exists concerning exactly who should be administering this follow‐up care. Here, we undertake a review of the current approaches described in the literature to follow‐up patients with coeliac disease, and assess the efficacy of these differing models. We also explore future directions for the care of these patients in the context of the UK National Health Service (a publicly funded healthcare system). Although the focus of this review pertains to follow‐up within the UK healthcare system, these problems are recognised to be international, and so the findings of our review are likely to be of interest to all healthcare professionals seeing and managing patients with coeliac disease.

show abstract

Interest in medical therapy for celiac disease

Abstract: Most individuals with celiac disease are interested in using a medication. Interest was highest among men, older individuals, frequent restaurant customers, individuals dissatisfied with their weight or concerned with the cost of a gluten-free diet, and those with a worse quality of life.

Cited by 36 publications

References 24 publications

The economic burden of gluten‐free products and gluten‐free diet: a cost estimation analysis in Greece

The economic burden of gluten‐free products and gluten‐free diet: a cost estimation analysis in Greece

Latiglutenase Improves Symptoms in Seropositive Celiac Disease Patients While on a Gluten-Free Diet

Long‐term care for patients with coeliac disease in the UK: a review of the literature and future directions

Contact Info

Product

Resources

About